Literature DB >> 26642339

Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood.

C Solano1,2, E Giménez3, J L Piñana1, V Vinuesa3, S Poujois3, S Zaragoza3, M Calabuig1, D Navarro3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26642339     DOI： 10.1038/bmt.2015.303

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

1.  Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation.

Authors:  V C Emery; C A Sabin; A V Cope; D Gor; A F Hassan-Walker; P D Griffiths
Journal:  Lancet       Date:  2000-06-10       Impact factor: 79.321

2.  Interlaboratory comparison of cytomegalovirus viral load assays.

Authors:  X L Pang; J D Fox; J M Fenton; G G Miller; A M Caliendo; J K Preiksaitis
Journal:  Am J Transplant       Date:  2009-02       Impact factor: 8.086

3.  Regression modeling of competing risk using R: an in depth guide for clinicians.

Authors:  L Scrucca; A Santucci; F Aversa
Journal:  Bone Marrow Transplant       Date:  2010-01-11       Impact factor: 5.483

4.  Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients.

Authors:  Concepción Gimeno; Carlos Solano; José C Latorre; Juan C Hernández-Boluda; María A Clari; María J Remigia; Santiago Furió; Marisa Calabuig; Nuria Tormo; David Navarro
Journal:  J Clin Microbiol       Date:  2008-08-27       Impact factor: 5.948

5.  Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies.

Authors:  Beatriz Muñoz-Cobo; Carlos Solano; Elisa Costa; Dayana Bravo; María Ángeles Clari; Isabel Benet; María José Remigia; Juan Montoro; David Navarro
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-24       Impact factor: 5.742

6.  Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain.

Authors:  Carlos Solano; Rafael de la Cámara; Lourdes Vázquez; Javier López; Estela Giménez; David Navarro
Journal:  J Clin Microbiol       Date:  2015-06-10       Impact factor: 5.948

7.  Comparative evaluation of three commercial quantitative cytomegalovirus standards by use of digital and real-time PCR.

Authors:  R T Hayden; Z Gu; S S Sam; Y Sun; L Tang; S Pounds; A M Caliendo
Journal:  J Clin Microbiol       Date:  2015-02-18       Impact factor: 5.948

8.  Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center.

Authors:  C Solano; B Muñoz-Cobo; E Giménez; M J Remigia; P Amat; M A Clari; D Bravo; I Benet; J Montoro; D Navarro
Journal:  Bone Marrow Transplant       Date:  2013-01-21       Impact factor: 5.483

9.  Management of cytomegalovirus infection in haemopoietic stem cell transplantation.

Authors:  Vincent Emery; Mark Zuckerman; Graham Jackson; Celia Aitken; Husam Osman; Anthony Pagliuca; Mike Potter; Karl Peggs; Andrew Clark
Journal:  Br J Haematol       Date:  2013-05-06       Impact factor: 6.998

10.  Comparative evaluation of three automated systems for DNA extraction in conjunction with three commercially available real-time PCR assays for quantitation of plasma Cytomegalovirus DNAemia in allogeneic stem cell transplant recipients.

Authors:  Dayana Bravo; María Ángeles Clari; Elisa Costa; Beatriz Muñoz-Cobo; Carlos Solano; María José Remigia; David Navarro
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948
View more
  7 in total

1.  The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.

Authors:  E Albert; C Solano; E Giménez; D Focosi; A Pérez; L Macera; J L Piñana; J C H Boluda; F Maggi; D Navarro
Journal:  Bone Marrow Transplant       Date:  2017-10-30       Impact factor: 5.483

2.  When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?

Authors:  C Solano; E Giménez; J L Piñana; J C Hernández-Boluda; P Amat; V Vinuesa; D Navarro
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

3.  PTX3 Polymorphisms Influence Cytomegalovirus Reactivation After Stem-Cell Transplantation.

Authors:  Cláudia F Campos; Luís Leite; Paulo Pereira; Carlos Pinho Vaz; Rosa Branca; Fernando Campilho; Fátima Freitas; Dário Ligeiro; António Marques; Egídio Torrado; Ricardo Silvestre; João F Lacerda; António Campos; Cristina Cunha; Agostinho Carvalho
Journal:  Front Immunol       Date:  2019-01-31       Impact factor: 7.561

4.  Cytomegalovirus in Adult Allogeneic Blood and Marrow Transplant Patients Before or Around the Period of Neutrophil Recovery: A Single-Center, Retrospective, Descriptive Study.

Authors:  Isabella Martin; Alexandra Valsamakis; Douglas Gladstone; Richard Jones; Richard Ambinder; Robin K Avery
Journal:  Open Forum Infect Dis       Date:  2020-03-09       Impact factor: 3.835

5.  Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia.

Authors:  José Luis Piñana; Estela Giménez; María Dolores Gómez; Ariadna Pérez; Eva María González; Víctor Vinuesa; Juan Carlos Hernández-Boluda; Juan Montoro; Miguel Salavert; Mar Tormo; Paula Amat; Paula Moles; Carlos Carretero; Aitana Balaguer-Roselló; Jaime Sanz; Guillermo Sanz; Carlos Solano; David Navarro
Journal:  J Infect       Date:  2019-02-21       Impact factor: 6.072

6.  Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections.

Authors:  José Luis Piñana; María Dolores Gómez; Ariadna Pérez; Silvia Madrid; Aitana Balaguer-Roselló; Estela Giménez; Juan Montoro; Eva María González; Víctor Vinuesa; Paula Moles; Juan Carlos Hernández-Boluda; Miguel Salavert; Marisa Calabuig; Guillermo Sanz; Carlos Solano; Jaime Sanz; David Navarro
Journal:  Transpl Infect Dis       Date:  2018-06-22       Impact factor: 2.228

7.  The Potential Harm of Cytomegalovirus Infection in Immunocompetent Critically Ill Children.

Authors:  Raidan Alyazidi; Srinivas Murthy; Jennifer A Slyker; Soren Gantt
Journal:  Front Pediatr       Date:  2018-04-10       Impact factor: 3.418
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.